A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
Authors:Robert A Kloner|||Paul Goggin|||Irwin Goldstein|||Geoffrey Hackett|||Michael G Kirby|||Ian Osterloh|||John D Parker|||Richard Sadovsky
Journal: Journal of cardiovascular pharmacology and therapeutics
Publication Type: Journal Article
Date: 2018
DOI: 10.1177/1074248418771896
ID: 29739235
Affiliations:
Affiliations
1 Huntington Medical Research Institutes, Pasadena, CA, USA.|||3 Pfizer Ltd, Sandwich, United Kingdom.|||4 Sexual Medicine, Alvarado Hospital, San Diego, CA, USA.|||5 Good Hope Hospital, Birmingham, United Kingdom.|||6 Health & Human Sciences, Centre for Research in Primary & Community Care, University of Hertfordshire, Hatfield, United Kingdom.|||7 OsterMed, Birmingham, United Kingdom.|||8 Division of Cardiology, Department of Medicine, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada.|||9 State University of New York, Downstate Medical Center, Brooklyn, NY, USA.
Abstract
Nitrates and nitrate-containing compounds are vasodilators used for the treatment of angina and heart failure. Phosphodiesterase type 5 inhibitors used for the treatment of erectile dysfunction are also vasodilators, and when taken together with nitrates, synergistic effects that enhance hypotensive effects may occur. Phosphodiesterase type 5 inhibitors are therefore contraindicated in patients taking organic nitrates.
